SynAct Pharma: 40mg Best Dose in ADVANCE - Redeye

Redeye views the topline data as confirming a bell-shaped dose-response with resomelagon. While the topline DAS28-CRP improvement was not statistically significant (p=0.168), the similar secondary endpoint ACR20 was borderline (p=0.06). We view the results as supporting further development.

Länk till analysen i sin helhet: https://www.redeye.se/research/1172191/synact-pharma-40mg-best-dose-in-advance?utm_source=finwire&utm_medium=RSS